Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEM-288 + nivolumab
- Development stage
- Phase 1
- Lead developer
- Memgen
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
MEM-288 + nivolumab is a combination therapy consisting of an oncolytic adenovirus (MEM-288) and an immune checkpoint inhibitor (nivolumab). MEM-288 is engineered to express interferon beta (IFNβ) and a membrane-stable version of CD40 ligand (MEM40), providing a triple mechanism of action: selective tumor cell destruction, immune stimulation via CD40 pathway activation, and antitumor effects of interferon. Nivolumab is a PD-1 inhibitor that prevents cancer cells from evading immune detection. The combination aims to generate synergistic antitumor immune responses, particularly in patients who have progressed on prior immunotherapy.
02
Targets
CD40 (Cluster of differentiation 40 receptor)CXADR (Coxsackievirus and adenovirus receptor)PDCD1 (Programmed cell death protein 1 receptor)IFNAR (Immune system modulation via type I interferon receptor)CD40LG (CD40 ligand extracellular domain)IFN-β (Interferon beta)
Beyond the preview
Go deeper on MEM-288 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEM-288 + nivolumab.